Society

ArcelorMittal S.A.: ArcelorMittal breaks ground on first transformational low-carbon emissions steelmaking project

Retrieved on: 
Thursday, October 13, 2022
News, Trust, Government, Carbon footprint, EAF, Coal, Woman, Federal Economic Development Initiative for Northern Ontario, Natural gas, Minister of Innovation, Science and Industry, Society, Dofasco, CAD, Carbon, Decarbonisation measures in proposed UK electricity market reform, Biomass, MTS, Man, Social change, Collaboration, Technology, Investment, Partnership, Friends, Company, Ministry of Economic Development, Job Creation and Trade, EV, US, Economic development, CEO, Avdiivka Coke Plant, Steel, Iron, MSCI EAFE, Maintenance, Foundation, Environment, Hydrogen, Federal Economic Development Agency for Southern Ontario, Heart, Engineering, DRI, Oil, Renewable energy, Creative industries, Iron ore, Industry, Science, ArcelorMittal

By investing in ArcelorMittal Dofascos project to produce clean steel, were investing in the future of this plant and this industry.

Key Points: 
  • By investing in ArcelorMittal Dofascos project to produce clean steel, were investing in the future of this plant and this industry.
  • Canadian steel companies are world-class and this project places Canadian workers at the heart of the future of the steel industry.
  • This project will enable ArcelorMittal Dofasco to produce cleaner, greener steel, while ensuring low-carbon manufacturing.
  • In addition to the transformation project in Hamilton, ArcelorMittal has also announced planned investments in decarbonisation technologies at its steelmaking facilities in Belgium , France andSpain.

Dosis Demonstrates 40% Reduction in Epoetin Beta Utilization with Maintained Hemoglobin Levels

Retrieved on: 
Friday, October 14, 2022
Software, Biotechnology, Pharmaceutical, Health, Diabetes, Artificial Intelligence, Health Technology, Technology, Adoption, Methoxy polyethylene glycol-epoetin beta, ASN, Dialysis, Efficiency, Science, Society, Patient, Multimedia, Artificial intelligence, Precision medicine, Technology, SAA, Anemia, Industry, ESA, Patient safety, 2021 Essex County Council election, Nephrology, Pharmaceutical industry, Medical device, Dose

View the full release here: https://www.businesswire.com/news/home/20221014005354/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221014005354/en/
    Figure 1: The abstract titled Artificial Intelligence (AI) Tool Decreases Epoetin Beta (Mircera) Drug Exposure and Maintains Hemoglobin at Desired Levels'' presents a 40% reduction in mean monthly epoetin beta dose using SAA, from 140 micrograms per patient per month to 84 micrograms per patient per month, with maintained hemoglobin levels.
  • (Graphic: Business Wire)
    One abstract, titled Artificial Intelligence (AI) Tool Decreases Epoetin Beta (Mircera) Drug Exposure and Maintains Hemoglobin at Desired Levels, analyzes clinical data from 2,116 patients receiving epoetin beta in 19 dialysis clinics.
  • Mean monthly dose of epoetin beta fell 40% using SAA, from 140 micrograms per patient per month to 84 micrograms per patient per month.
  • The two clinics that discontinued SAA use during the analyzed period saw hemoglobin levels fall by 0.6 g/dL and monthly epoetin beta dose per patient rise by 50-57%.

University of Detroit Mercy Selects YuJa’s Video Platform to Serve Seven Colleges and Schools

Retrieved on: 
Friday, October 14, 2022
Education, Technology, Audio, Video, University, Online video platform, Government, Roposo, Inside Higher Ed, Organization, The Society of Jesus, University of Detroit Mercy, Yuzu, University, Student, Catholic (term), Microsoft PowerPoint, Society, Â, Religious Sisters of Mercy, Dentistry, Silicon, School, Medicine, Education

The University of Detroit Mercy has selected the YuJa Enterprise Video Platform to replace its former video content management and streaming services.

Key Points: 
  • The University of Detroit Mercy has selected the YuJa Enterprise Video Platform to replace its former video content management and streaming services.
  • The Video Platform, which will be available to students and instructors at seven colleges and schools, will enable the schools that comprise the institution with an all-in-one solution to record, edit, caption and distribute video and other content.
  • Founded in 1877 by the Society of Jesus (the Jesuits), University of Detroit Mercy is Michigans largest and most comprehensive Catholic university.
  • In 1990, University of Detroit consolidated with Mercy College of Detroit, which was founded in 1941 by the Religious Sisters of Mercy, to form University of Detroit Mercy.

 Plexision launches personalized transplant diagnostic testing in India

Retrieved on: 
Friday, October 14, 2022
Biotechnology, Venture Capital, Health, Professional Services, Pharmaceutical, Degenerative disease, Global depository receipt, Risk, Hospital, Population, Infection, Vaccine, GMP, Patient, Kidney, Cytomegalovirus, Immunodeficiency, Society, CEO, Organ transplantation, Liver, Donation, Genetic testing, Survival, FDA, COVID-19, Cancer, Sir, Liver transplantation, Dentistry, MD, Transplant

Plexision, a US-based biotechnology company, has initiated overseas operations with the establishment of a reference laboratory in Hyderabad, India.

Key Points: 
  • Plexision, a US-based biotechnology company, has initiated overseas operations with the establishment of a reference laboratory in Hyderabad, India.
  • These tests include the companys exclusive personalized transplant diagnostic tests to predict rejection and viral infections, as well as drug level monitoring, pharmacogenomics, and genetic testing.
  • Plexisions test systems can define this complex makeup to personalize care and improve outcomes in the rapidly growing transplant recipient population in India said Rajeev Sindhi, CEO of Plexision.
  • About Plexision: Plexision performs cell-based blood tests for personalized management of transplant rejection, infections in immunocompromised patients, and immune therapy in oncology.

Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American Society of Nephrology’s Kidney Week 2022 Annual Meeting

Retrieved on: 
Friday, October 14, 2022
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, ASN, Disease, Lupus nephritis, Pathology, Lee, Ohio State University Wexner Medical Center, Degenerative disease, Society, FACP, Patient, Division, Annual general meeting, Nasdaq, Treatment, MD, Immunosuppression, Sec61, Congress, Safety, 2021 Essex County Council election, Associate, International Association for Mission Studies, Ohio State University, FASN, Medicine, List of life sciences, Pharmaceutical industry, Nephrology

Of note, the Phase 2 MISSION poster will include the full data set from the concluded study, with all 17 evaluable patients completing the 37-week trial.

Key Points: 
  • Of note, the Phase 2 MISSION poster will include the full data set from the concluded study, with all 17 evaluable patients completing the 37-week trial.
  • There will be additional MISSION data included in the poster presentation that are not available in the abstract.
  • Following the conference, the presentation materials will be available in the Scientific Publications section of Kezar Life Sciences website at www.kezarlifesciences.com .
  • Zetomipzomib, its lead development asset, is a selective immunoproteasome inhibitor being evaluated in a Phase 2 clinical trial in lupus nephritis.

SkyHive Joins Responsible Artificial Intelligence Institute

Retrieved on: 
Thursday, October 13, 2022
Software, Technology, Artificial Intelligence, Global Partnership on Artificial Intelligence, SkyHive, Certification, Forbes, RAII, Software as a service, Organization, World Economic Forum, Policy, Intelligence, OECD, Partnership, Technology, Non-governmental organization, Software, AI, RAI, CEO, Patent, Safety, Artificial intelligence, Map, Solution, Compliance, Society, Medical device

SkyHive , the first company to map and sequence the global labor market in real-time, provide workforce intelligence, and guide the rapid reskilling of workers and communities around the world, today announced it has joined the Responsible Artificial Intelligence Institute (RAII), an independent non-profit organization creating governance standards and certifications for AI systems and scalable solutions for practitioners.

Key Points: 
  • SkyHive , the first company to map and sequence the global labor market in real-time, provide workforce intelligence, and guide the rapid reskilling of workers and communities around the world, today announced it has joined the Responsible Artificial Intelligence Institute (RAII), an independent non-profit organization creating governance standards and certifications for AI systems and scalable solutions for practitioners.
  • We are pleased to welcome SkyHive into RAII as our newest member, said Ashley Casovan, Executive Director of RAII.
  • It has gained recognition from OECD and the Global Partnership on Artificial Intelligence and has established itself as a clear pioneer of purpose-driven and socially beneficial AI.
  • Responsible AI Institute (RAII) is a 501(c)(3) non-profit focused on advancing responsible AI from principles to practice through community-driven, independent AI assessments and certifications.

Nutcracker Therapeutics to Present Data for Lead Candidate at 2022 SITC Annual Meeting

Retrieved on: 
Thursday, October 13, 2022
Research, Genetics, Clinical Trials, Health Technology, Biotechnology, Biometrics, Health, Science, Oncology, Therapy, Nutcracker, Immunotherapy, SITC, Neoplasm, JITC, RNA, Society, 2021 Essex County Council election, Journal, EST, HPV, Cancer, Society for Immunotherapy of Cancer, Vaccine

Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today announced the upcoming poster presentation of new preclinical data for its lead therapeutic candidate, NTX-0250, which targets human papillomavirus (HPV)-driven cancers.

Key Points: 
  • Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today announced the upcoming poster presentation of new preclinical data for its lead therapeutic candidate, NTX-0250, which targets human papillomavirus (HPV)-driven cancers.
  • The company will present this data at the 37th annual meeting of the Society for Immunotherapy of Cancer (SITC), being held in Boston, MA, from November 8-12, 2022.
  • The poster presentation will showcase data that demonstrates that NTX-0250, a multimodal, mRNA-based therapeutic, is capable of inducing the complete regression of large murine tumors.
  • For more information about the 37th SITC annual meeting, please visit https://www.sitcancer.org/home .

"New initiative asks all Canadians to help grow the Network of Nature"

Retrieved on: 
Friday, October 14, 2022
Geography, Risk, Toronto Zoo, City, Network, Natural Resources, Population, Department for Environment, Food and Rural Affairs, Animal, Australian Environment Foundation, Architecture, Tree, Soil, Volunteering, Associate, Bank, Canadian Geographic Education, Seed, Carbon, Program, Ontario Ministry of Citizenship and Immigration, Collection, TD, D, RCGS, OMAFRA, Canadian Council on Animal Care, Biodiversity, Knowledge, Plant, Food, Conservation, Royal Canadian Geographical Society, Exercise, CCAC, Health, Education, Society, Association, Friends, CEO, Board, D&A, Partnership, AZA, Environment, Canada's Accredited Zoos and Aquariums, Database, Water resources, Gardening, Zoo, Renewable energy, Hunting, Forestry, Nature, Agriculture, Canadian Geographic

With the help of individual Canadians, governments, and corporate landowners, we can reverse this trend."

Key Points: 
  • With the help of individual Canadians, governments, and corporate landowners, we can reverse this trend."
  • Working to engage all Canadians, the Network of Nature is a national movement to restore native plant biodiversity using balconies, backyards, and boulevards across Canada.
  • I encourage every other Canadian to provide what land they can to help grow the Network of Nature."
  • This tool will help individual Canadians, developers, corporate property managers and landscape architects select and source appropriate native plants, seeds and trees locally.

Bold Therapeutics Attending and Presenting at the BIO-Europe 2022 and BIO-Europe 2022 Virtual Conferences

Retrieved on: 
Friday, October 14, 2022
GRP78, Therapy, Conference, ASCO, Society, Patient, Induced cell cycle arrest, Unfolded protein response, Confidentiality, Annual general meeting, Multimedia, UPR, Cell death, ROS, Gastrointestinal cancer, Reactive oxygen species, DNA, FOLFOX, Breakthrough therapy, Cancer, View, DNA repair, Pharmaceutical industry, BC

VANCOUVER, BC, Oct. 14, 2022 /PRNewswire/ -- Bold Therapeutics, a clinical-stage biopharmaceutical company, announced that they are attending the BIO-Europe 2022 conference in Leipzig, Germany from October 24 26, as well as presenting at the BIO-Europe Virtual Conference from November 2 - 4.

Key Points: 
  • VANCOUVER, BC, Oct. 14, 2022 /PRNewswire/ -- Bold Therapeutics, a clinical-stage biopharmaceutical company, announced that they are attending the BIO-Europe 2022 conference in Leipzig, Germany from October 24 26, as well as presenting at the BIO-Europe Virtual Conference from November 2 - 4.
  • Bold Therapeutics presented initial data from this Phase 2 trial at the 2022 American Society of Cancer Oncology (ASCO) Annual Meeting in June 2022.
  • Consequently, Bold Therapeutics expects to receive a Breakthrough Therapy Designation in the treatment of 3rd line or later treatment-resistant metastatic colorectal cancer (mCRC) and potentially other gastrointestinal cancer indications as well.
  • Bold Therapeutics expects to present this robust data set at a major cancer conference in early 2023.

C-Path's Transplant Therapeutics Consortium receives EMA Draft Qualification Opinion for the iBox Scoring System

Retrieved on: 
Friday, October 14, 2022
AST, U.S. Department of Defense Strategy for Operating in Cyberspace, TTC, Health care, Therapy, European Medicines Agency, Life, Dialysis, IBox, Review, Government, SOC, EMA, Ammonia, Food and Drug Administration, Proteinuria, Banff, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IST, Patient, Drug development, Society, Standard of care, HHS, Transplant, Multimedia, Partnership, Unitary state, Food, Transplant surgeon, Asahi Kasei, CEO, Biopsy, Critical Path Institute, Office of Inspector General, U.S. Department of Health and Human Services, FDA, Solution, EGFR, Pharmaceutical industry, Dentistry, Veloxis Pharmaceuticals

CARY, N.C., Oct. 14, 2022 /PRNewswire/ -- Critical Path Institute (C-Path) announced October 13, 2022 that its Transplant Therapeutic Consortium (TTC), of which Veloxis Pharmaceuticals is a member, received a draft qualification opinion for the iBox Scoring System through the European Medicines Agency's (EMA) qualification of novel methodologies for drug development. This significant qualification means that the iBox Scoring System, which supports the evaluation of novel immunosuppressive therapy (IST) applications with EMA, will soon be available to be used as a secondary efficacy endpoint in kidney transplant clinical trials.

Key Points: 
  • This significant qualification means that the iBox Scoring System, which supports the evaluation of novel immunosuppressive therapy (IST) applications with EMA, will soon be available to be used as a secondary efficacy endpoint in kidney transplant clinical trials.
  • The draft qualification opinion is going through a public consultation stage through Nov. 17, 2022.
  • Improving the long-term outcomes in kidney transplant recipients is the ultimate goal and, as such, the qualification of the iBox Scoring System has been TTC's primary initiative since its inception in 2017.
  • "Veloxis is proud to be a part of the Transplant Therapeutics Consortium and the incredible work to achieve draft qualification opinion status for the iBox Scoring System," says Mark Hensley, CEO of Veloxis.